P. Jeffrey Conn

发表

[Table, Synthetic procedure (large scale) and spectral data for ML172 (CID 44602489)].

Thomas M. Bridges, L. Michelle Lewis, C. David Weaver, 2013 .

Figure 2, LY2033298 and cheminformatics and database mining approach which lead to the first M4 probe compound (CID 864492)

Thomas M. Bridges, L. Michelle Lewis, C. David Weaver, 2013 .

Table 2, Ricerca Profiling of ML337

P. Jeffrey Conn, Julie L. Engers, Cody J. Wenthur, 2013 .

Figure 3, Optimization strategy for CID 42633508, a highly M5-preferring PAM

Thomas M. Bridges, L. Michelle Lewis, C. David Weaver, 2013 .

Figure 4, Comparison of the key profiles of the known M4 PAM art and ML253

Michael R. Wood, J. Scott Daniels, P. Jeffrey Conn, 2013 .

Figure 6, CRC overlay of muscarinic rM1 – rM5 selectivity profile for ML326 (VU0467903)

Peter Hodder, Thomas M. Bridges, Michael R. Wood, 2013 .

Figure 5, CRC overlay for CID 2145491

Peter Hodder, Thomas M. Bridges, Michael R. Wood, 2013 .

Table 5, Pan Labs profiling of ML326 and selected results for ML172

Peter Hodder, Thomas M. Bridges, Michael R. Wood, 2013 .

Jeffrey Conn-Opportunities and Challenges for Drug Discovery in a Postgenomic World

P. Jeffrey Conn, 2007 .

Table 1, Ricerca Profiling of ML289

P. Jeffrey Conn, Eric S. Dawson, Julie L. Engers, 2013 .

[Table, Synthetic procedure (large scale) and spectral data for ML173 (CID 45142486)].

Thomas M. Bridges, L. Michelle Lewis, C. David Weaver, 2013 .

N-{4-Chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide (CPPHA) Acts through a Novel Site as a Positive Allosteric Modulator of Group 1 Metabotropic Glutamate Receptors

P. Jeffrey Conn, J. Pin, P. Conn, 2008, Molecular Pharmacology.

Discovery and SAR of muscarinic receptor subtype 1 (M1) allosteric activators from a molecular libraries high throughput screen. Part 1: 2,5-dibenzyl-2H-pyrazolo[4,3-c]quinolin-3(5H)-ones as positive allosteric modulators.

Peter Hodder, P. Jeffrey Conn, Craig W. Lindsley, 2015, Bioorganic & medicinal chemistry letters.

Metabotropic glutamate receptor-induced disinhibition is mediated by reduced transmission at excitatory synapses onto interneurons and inhibitory synapses onto pyramidal cells

P. Jeffrey Conn, Chris J. McBain, J. Kauer, 1994, Neuroscience Letters.

Tackling reproducibility in academic preclinical drug discovery

Michelle R. Arkin, Marcie A. Glicksman, P. Jeffrey Conn, 2015, Nature Reviews Drug Discovery.

Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders

Arthur Christopoulos, P. Jeffrey Conn, Craig W. Lindsley, 2009, Nature Reviews Drug Discovery.

A Close Structural Analog of 2-Methyl-6-(phenylethynyl)-pyridine Acts as a Neutral Allosteric Site Ligand on Metabotropic Glutamate Receptor Subtype 5 and Blocks the Effects of Multiple Allosteric Modulators

P. Jeffrey Conn, David Alagille, P. Conn, 2005, Molecular Pharmacology.

Metabotropic glutamate receptors in the basal ganglia motor circuit

P. Jeffrey Conn, Giuseppe Battaglia, F. Nicoletti, 2005, Nature Reviews Neuroscience.

N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-d-aspartate receptor activity

P. Jeffrey Conn, E. Scolnick, P. Mallorga, 2003, Proceedings of the National Academy of Sciences of the United States of America.

Identification of Metabotropic Glutamate Receptor Subtype 5 Potentiators Using Virtual High-Throughput Screening

Jens Meiler, C. David Weaver, P. Jeffrey Conn, 2010, ACS chemical neuroscience.

Novel Allosteric Agonists of M1 Muscarinic Acetylcholine Receptors Induce Brain Region-Specific Responses That Correspond with Behavioral Effects in Animal Models

M. Foster Olive, J. Scott Daniels, P. Jeffrey Conn, 2012, The Journal of Neuroscience.

Bringing together the academic drug discovery community

P. Jeffrey Conn, Michelle Arkin, Stephen Frye, 2013, Nature Reviews Drug Discovery.

Allosteric modulation of metabotropic glutamate receptors: Structural insights and therapeutic potential

Jens Meiler, P. Jeffrey Conn, K. Gregory, 2011, Neuropharmacology.

Development of allosteric modulators of GPCRs for treatment of CNS disorders

P. Jeffrey Conn, P. Conn, Hilary Highfield Nickols, 2014, Neurobiology of Disease.

Molecular Pharmacology in the Postgenomic Era

P. Jeffrey Conn, 2006 .

mGluR5 positive allosteric modulators facilitate both hippocampal LTP and LTD and enhance spatial learning

M. Foster Olive, P. Jeffrey Conn, Craig W. Lindsley, 2009, Neuropsychopharmacology.

Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders

Jens Meiler, P. Jeffrey Conn, Craig W. Lindsley, 2014, Nature Reviews Drug Discovery.